Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Intersect ENT  (Stock symbol: XENT )

1555 Adams Drive
Menlo Park, CA 94025
USA
650.641.2100
Website Company Summary Management Team
Management

CEO: Thomas A. West (7/31/2019)
President/COO/Operations: Christine Kowalski ; Rich Kaufman (01/31/2007)
General Management: Amy Conuel Wolbeck (1/31/2009) ; Conuel Wolbeck (1/31/2009) ; James Stambaugh (10/31/2006)
Finance: Randy Meier (12/2/2019)
Technology: Virginia Giddings (1/31/2019)
Board

Outside board: (May no longer be on the board) Dana Mead (Kleiner Perkins Partner);  Mark Fletcher (Medtronic Division President) Cynthia L. Lucchese (Hillenbrand Former CFO) Rick D. Anderson (PTV Sciences Managing Director) Frederick H. Moll (Restoration Robotics Chairman) Casey Tansey (Epicor Medical);  Casper de Clercq (Norwest Venture Partners Venture Partner)
Former outside board: Evan S. Melrose (PTV Sciences Managing Director)
Company

Business description: Intersect ENT's mission is to advance clinically proven therapy solutions that enable ear, nose, and throat (ENT) physicians to solve clinical challenges and improve the quality of life for patients. Located in Palo Alto, CA, Intersect ENT's initial focus is chronic sinusitis, a condition that affects one out of seven adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.1,15 For these chronic sinus sufferers, their condition deeply impacts their quality of life and often requires a complex combination of medical and surgical therapy. While surgical solutions relieve symptoms in many patients, disease can recur even in the postoperative period; the majority have symptoms that persist within the first year; 25% require another surgery.16 We at Intersect ENT believed there had to be a better way -- to improve both the patient experience and surgical outcomes as well as alleviate physician frustration with disease recurrence. We developed the PROPEL steroid-releasing implant with these goals in mind. PROPEL props open the ethmoid sinus cavity following surgery and allows for localized delivery of steroid directly to the sinus mucosa, as it dissolves. For patients, this may mean less invasive treatment options, improved surgical outcomes, and reduced need for systemic drugs such as oral steroids which can lead to serious side effects.
Capital

Rounds: 4
Recent Fundings: Jun 2020   Sep 2011
Capital raised: 79.3M
Last Round: 30.0M
Ownership: Public   Ipo Filing
Stock Symbol: XENT
Corporate investors: DURECTMedtronic

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2021
Sector: Medical
Year Founded: 2003
Headcount: 301-400 as of Jul 2021
Rounds: 4
Recent Fundings: Jun 2020   Sep 2011
Capital Raised: 79.3M
Last Round: 30.0M
Ownership: Public   Ipo Filing
Stock Symbol: XENT